DelveInsight’s “Tyrosine kinase 2 (TYK2) Inhibitors Target Population, Competitive Landscape, and Market Forecast – 2034” report delivers an in-depth understanding of the TYK2 inhibitors, historical and competitive landscape, as well as its market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Discover which indication is expected to grab the major TYK2 inhibitors market share @ https://www.delveinsight.com/sample-request/tyrosine-kinase-2-tyk2-inhibitors-market-forecast
Key Takeaways from the TYK2 Inhibitors Market Report
- In March 2025, Alumis announced positive 52-week data from the open-label extension of its Phase II STRIDE clinical trial evaluating ESK-001 in patients with moderate-to-severe plaque psoriasis. The results were presented during a late-breaking session at the 2025 American Academy of Dermatology Association (AAD) Annual Meeting 2025.
- The diagnosed prevalent cases of SLE in 7MM in 2024 were nearly 1,053,700.
- In the US, plaque psoriasis is estimated to manifest in 2–3% of the adult population, with moderate-to-severe plaque psoriasis developing in approximately 20% of patients with plaque psoriasis.
- Among the EU4 and the UK, Germany accounted for the highest number of cases of hidradenitis suppurativa, followed by the UK and the lowest number of cases in Spain in 2024.
- Japan accounted for nearly 74,150 diagnosed prevalent cases of Crohn’s disease in 2024.
- The leading TYK2 Inhibitors Companies such as Bristol-Myers Squibb, Priovant Therapeutics, Alumis, Galapagos, Takeda, Oncostellae, and others.
- Promising TYK2 Inhibitors Therapies such as Brepocitinib, Zasocitinib, ESK-001, GLPG3667, OST-122, NEU-111, and others.
Learn more about the TYK2 inhibitors Competitive Landscape Report @ TYK2 Inhibitors Analysis
TYK2 Inhibitors Marketed Therapies
- SOTYKTU (deucravacitinib): Bristol-Myers Squibb
SOTYKTU is a selective, allosteric inhibitor of TYK2. TYK2 is a member of the JAK family. SOTYKTU binds to the regulatory domain of TYK2, stabilizing an inhibitory interaction between the regulatory and the catalytic domains of the enzyme. This results in allosteric inhibition of receptor-mediated activation of TYK2 and its downstream activation of Signal Transducers and Activators of Transcription (STATs) as shown in cell-based assays. Janus kinases function as pairs of homo- or heterodimers in the JAK-STAT pathways. TYK2 pairs with JAK1 to mediate multiple cytokine pathways and also pairs with JAK2 to transmit signals as shown in cell-based assays. The precise mechanism linking inhibition of TYK2 enzyme to therapeutic effectiveness in the treatment of adults with moderate-to-severe plaque psoriasis is not currently known. The therapy is approved for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
TYK2 Inhibitors Emerging Therapies
- ESK-001: Alumis
ESK-001 is a TYK2 inhibitor that reduces signaling through several cytokine receptors including receptors for interleukin (IL)-23, and type 1 interferon. ESK-001 has the potential to reduce SLE disease activity by interfering with pro-inflammatory pathways known to be involved in the pathogenesis of SLE. It is being evaluated in Phase II.
- Brepocitinib: Priovant Therapeutics
Priovant’s lead molecule is brepocitinib, an oral once-daily dual inhibitor of TYK2 and JAK1. By selectively inhibiting both TYK2 and JAK1, brepocitinib is optimized to suppress signaling of a wide range of TYK2- and JAK1-dependent cytokines linked to autoimmunity, including type I and type II interferon, IL-6, IL-12, and IL-23. Priovant is developing brepocitinib across multiple severe autoimmune diseases. The company is currently running the VALOR Study, a fully enrolled single registrational Phase III trial evaluating brepocitinib in dermatomyositis patients, with top-line results expected in 2025. The company also recently initiated the Phase III CLARITY Study of brepocitinib in Non-infectious Uveitis (NIU), following successful results from the Phase II NEPTUNE Study. Priovant plans to initiate a Phase II study of brepocitinib in cutaneous sarcoidosis in 2025.
To know more about TYK2 inhibitors clinical trials, visit @ TYK2 Inhibitors Treatment
TYK2 Inhibitors Market Outlook
The global TYK2 inhibitor market is expected to witness substantial growth in the coming years, driven by the increasing prevalence of autoimmune diseases, robust clinical pipeline activity, and expanding regulatory approvals. Several key players, including Takeda, Alumis, Priovant Therapeutics, and others, are involved in developing drugs for TYK2 inhibitors such as Crohn’s disease, psoriasis, dermatomyositis, and others, respectively. Overall, this is an exciting new class with great potential for development. The maturation of current studies over the next few years will lead to a better understanding of TYK2 inhibitors and define their role in autoimmune indications.
TYK2 Inhibitors Market Dynamics
The TYK2 inhibitors market dynamics is emerging as a dynamic and rapidly evolving segment within the broader immunology and inflammation therapeutics space. Unlike broader JAK inhibitors that often target multiple JAK subtypes and are associated with off-target effects and safety concerns, selective TYK2 inhibitors offer a more targeted approach, potentially minimizing adverse effects while maintaining efficacy. This selectivity is a key driver of pharmaceutical interest and investor confidence in this class of drugs.
Discover more about TYK2 inhibitors in development @ TYK2 Inhibitors Clinical Trials
Scope of the TYK2 Inhibitors Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- Companies- Bristol-Myers Squibb, Priovant Therapeutics, Alumis, Galapagos, Takeda, Oncostellae, and others.
- TYK2 Inhibitors Therapeutic Assessment: TYK2 Inhibitors’ current marketed and emerging therapies
- TYK2 Inhibitors Market Dynamics: Conjoint Analysis of Emerging TYK2 Inhibitor Drugs
- TYK2 Inhibitors Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- TYK2 Inhibitors Unmet Needs, KOL’s views, Analyst’s views, TYK2 Inhibitors Market Access and Reimbursement
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of Tyrosine Kinase 2 (TYK2) Inhibitors
4. Key Events
5. Epidemiology Market Forecast Methodology of Tyrosine Kinase 2 (TYK2) Inhibitors
6. Tyrosine Kinase 2 (TYK2) Inhibitors Market Overview at a Glance in the 7MM
7. Tyrosine Kinase 2 (TYK2) Inhibitors: Background and Overview
8. Target Patient Pool of Tyrosine Kinase 2 (TYK2) Inhibitors
9. Marketed Tyrosine Kinase 2 (TYK2) Inhibitors
10. Emerging Tyrosine Kinase 2 (TYK2) Inhibitors
11. Tyrosine Kinase 2 (TYK2) Inhibitors: Seven Major Market Analysis
12. SWOT Analysis of Tyrosine Kinase 2 (TYK2) Inhibitors
13. KOL Views of Tyrosine Kinase 2 (TYK2) Inhibitors
14. Unmet Needs of Tyrosine Kinase 2 (TYK2) Inhibitors
15. Market Access and Reimbursement of Tyrosine Kinase 2 (TYK2) Inhibitors
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.
